As i understand it a company with a highly promising drug that has passed phase 2b can file to have approval granted after a 24 week dosing period in the phase III trial rather than the usual 48 weeks. If this approval is obtained then it is estimated that the cost of the trial will be reduced anywhere from 20% to 30%.
That's a saving of $15million to $23 million.
seek expert advice
- Forums
- ASX - By Stock
- AVX
- 24 week approval
24 week approval
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)